---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-279821"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:14:59.533091+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics receives Nasdaq deficiency notice for MVPHS below $5M

## Summary
- Received Nasdaq deficiency letter Nov 15, 2023 for failing MVPHS Rule 5450(b)(1)(C) for 35 consecutive days.
- Market value of publicly held shares below $5M minimum required for continued listing on Nasdaq Global Select Market.
- Compliance period through May 13, 2024; must meet $5M threshold for 10 consecutive business days to regain compliance.
- If non-compliant, company may consider transferring to Nasdaq Capital Market; delisting possible if not cured.

## SEC filing metadata
- accession: 0001193125-23-279821
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000119312523279821/0001193125-23-279821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000119312523279821/d405238d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-279821
- JSON: https://secwatch.observer/filing/0001193125-23-279821.json
- Plain text: https://secwatch.observer/filing/0001193125-23-279821.txt

## Key facts
- Listing & Compliance Notices
  Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(1)(C)
  source text: November 15, 2023, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 35 consecutive business days, it did not meet the requirement to have a market value of publicly held shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), of $5.0 million pursuant to Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Rule”). The deficiency letter has no immediate effect on the listing of the Common Stock on the Nasdaq Global Select
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000119312523279821/0001193125-23-279821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.